Last updated: 6 March 2024 at 7:42pm EST

Chad Robins Net Worth




The estimated Net Worth of Chad M Robins is at least $22.4 Milión dollars as of 4 March 2024. Mr. Robins owns over 48,673 units of Adaptive Biotechnologies stock worth over $11,311,717 and over the last 5 years he sold ADPT stock worth over $8,616,057. In addition, he makes $2,470,230 as Executive Chairman, Chief Executive Officer a Co-Founder at Adaptive Biotechnologies.

Mr. Robins ADPT stock SEC Form 4 insiders trading

Chad has made over 33 trades of the Adaptive Biotechnologies stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 48,673 units of ADPT stock worth $166,948 on 4 March 2024.

The largest trade he's ever made was exercising 150,000 units of Adaptive Biotechnologies stock on 19 May 2020 worth over $49,500. On average, Chad trades about 38,934 units every 43 days since 2020. As of 4 March 2024 he still owns at least 2,576,701 units of Adaptive Biotechnologies stock.

You can see the complete history of Mr. Robins stock trades at the bottom of the page.





Chad Robins biography

Chad M. Robins serves as Executive Chairman, Chief Executive Officer, Co-Founder of the Company. He is co-founded our company in September 2009 and has served as our Chief Executive Officer and a member of our board of directors since incorporation. Prior to co-founding our company, Mr. Robins held numerous executive-level positions in medical technology, investment and real estate companies. Mr. Robins holds an MBA from The Wharton School at the University of Pennsylvania and a BS in Managerial Economics from Cornell University.

What is the salary of Chad Robins?

As the Executive Chairman, Chief Executive Officer a Co-Founder of Adaptive Biotechnologies, the total compensation of Chad Robins at Adaptive Biotechnologies is $2,470,230. There are 1 executives at Adaptive Biotechnologies getting paid more, with Lance Baldo having the highest compensation of $3,707,390.



What's Chad Robins's mailing address?

Chad's mailing address filed with the SEC is C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVENUE EAST, SEATTLE, WA, 98109.

Insiders trading at Adaptive Biotechnologies

Over the last 5 years, insiders at Adaptive Biotechnologies have traded over $685,617,014 worth of Adaptive Biotechnologies stock. The most active insiders traders include Global Investors Lp Viking ..., Global Performance Llc Viki... a Kevin T Conroy. On average, Adaptive Biotechnologies executives and independent directors trade stock every 6 days with the average trade being worth of $368,167. The most recent stock trade was executed by Stacy L Taylor on 22 August 2024, trading 26,922 units of ADPT stock currently worth $121,149.



What does Adaptive Biotechnologies do?

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. It also has a research collaboration with Curebase, Inc. to enhance patient participation in clinical studies. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.



What does Adaptive Biotechnologies's logo look like?

Adaptive Biotechnologies Corporation logo

Complete history of Mr. Robins stock trades at Adaptive Biotechnologies

Dátum
#
Spoločnosť
Človek
Trans.
Transakcia
Počet akcií Cena za akciu Celková cena Počet akcií po Zdroj
4 Mar 2024 Chad M Robins
CEO a Predseda
Predaj 48,673 $3.43 $166,948
4 Mar 2024
2,576,701
7 Mar 2022 Chad M Robins
CEO a Predseda
Využitie opcie 44,445 $6.32 $280,892
7 Mar 2022
1,930,969
4 Mar 2022 Chad M Robins
CEO a Predseda
Predaj 4,424 $12.01 $53,132
4 Mar 2022
1,916,154
8 Sep 2021 Chad M Robins
CEO a Predseda
Predaj 43,499 $38.43 $1,671,667
8 Sep 2021
1,673,461
12 Jul 2021 Chad M Robins
CEO a Predseda
Predaj 1,501 $38.24 $57,398
12 Jul 2021
1,716,960
15 Jun 2021 Chad M Robins
CEO a Predseda
Predaj 30,000 $38.47 $1,154,100
15 Jun 2021
1,718,461
6 Apr 2021 Chad M Robins
CEO a Predseda
Predaj 15,000 $41.81 $627,150
6 Apr 2021
1,748,461
17 Mar 2021 Chad M Robins
CEO a Predseda
Predaj 15,000 $42.89 $643,350
17 Mar 2021
1,763,461
8 Feb 2021 Chad M Robins
CEO a Predseda
Predaj 30,000 $62.31 $1,869,300
8 Feb 2021
1,709,780
26 Jan 2021 Chad M Robins
CEO a Predseda
Predaj 30,000 $59.38 $1,781,400
26 Jan 2021
1,739,780
19 Jan 2021 Chad M Robins
CEO a Predseda
Predaj 8,400 $70.43 $591,612
19 Jan 2021
1,769,780
28 Dec 2020 Chad M Robins
CEO a Predseda
Využitie opcie 49,560 $0.33 $16,355
28 Dec 2020
1,794,700
17 Nov 2020 Chad M Robins
CEO a Predseda
Využitie opcie 50,040 $0.33 $16,513
17 Nov 2020
1,794,860
6 Oct 2020 Chad M Robins
CEO a Predseda
Využitie opcie 92,540 $0.33 $30,538
6 Oct 2020
1,802,440
29 Sep 2020 Chad M Robins
CEO a Predseda
Využitie opcie 2,500 $0.33 $825
29 Sep 2020
1,778,780
16 Sep 2020 Chad M Robins
CEO a Predseda
Využitie opcie 50,040 $0.33 $16,513
16 Sep 2020
1,794,860
10 Aug 2020 Chad M Robins
CEO a Predseda
Využitie opcie 50,040 $0.33 $16,513
10 Aug 2020
1,794,860
29 Jul 2020 Chad M Robins
CEO a Predseda
Využitie opcie 54,028 $0.33 $17,829
29 Jul 2020
1,794,860
22 Jun 2020 Chad M Robins
CEO a Predseda
Využitie opcie 33,132 $0.33 $10,934
22 Jun 2020
1,811,312
17 Jun 2020 Chad M Robins
CEO a Predseda
Využitie opcie 69,680 $0.33 $22,994
17 Jun 2020
1,802,740
19 May 2020 Chad M Robins
CEO a Predseda
Využitie opcie 150,000 $0.33 $49,500
19 May 2020
1,928,180
7 May 2020 Chad M Robins
CEO a Predseda
Využitie opcie 45,000 $0.33 $14,850
7 May 2020
1,923,180
13 Apr 2020 Chad M Robins
CEO a Predseda
Využitie opcie 50,040 $0.33 $16,513
13 Apr 2020
1,889,300
19 Mar 2020 Chad M Robins
CEO a Predseda
Využitie opcie 16,680 $0.33 $5,504
19 Mar 2020
1,883,740
13 Feb 2020 Chad M Robins
CEO a Predseda
Využitie opcie 11,120 $0.33 $3,670
13 Feb 2020
1,889,300
11 Feb 2020 Chad M Robins
CEO a Predseda
Využitie opcie 22,240 $0.33 $7,339
11 Feb 2020
1,889,300
27 Jan 2020 Chad M Robins
CEO a Predseda
Využitie opcie 33,360 $0.33 $11,009
27 Jan 2020
1,889,300


Adaptive Biotechnologies executives and stock owners

Adaptive Biotechnologies executives and other stock owners filed with the SEC include: